**PATENT** 



# Attorney Docket No. NUCL-006/01US **Application No. 10/560,377**

Page 1

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Catherine J. PACHUK et al.

Confirmation No.: 3823

Application No.: 10/560,377

Group Art Unit: To Be Assigned

Int'l. Filing Date: June 10, 2004

Examiner: To Be Assigned

For: Conserved HBV and HCV Sequences Useful for Gene Silencing

Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window, Mail Stop Amendment Randolph Building 401 Dulany Street Alexandria, VA 22314

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

- Pursuant to 37 C.F.R. §1.98, copies of documents 1-3 cited in the attached Form [x]PTO-1449 are enclosed.
- Copies of the remaining publications listed on the attached Form PTO-1449 are [] not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.: to which the above-identified application claims priority under 35 U.S.C. §120.
- Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
  - Should the Examiner be unable to locate a document, a copy will be provided upon request.
- No copies of any U.S. patents or U.S. patent application publications listed on the [ ] attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98.

[]	Document is the PCT Patent publications of Applicants' related PCT Application no, filed
[x]	Documents 2 and 3 were cited in an International Preliminary Report On Patentability mailed January 31, 2007 (cited herein as document 1), in Applicants' related PCT Application no. PCT/US04/19229.
[x]	Document 1 is an official communication from a foreign patent office received in Applicants' related PCT Application no. PCT/US04/19229.
[]	Documents submitted herewith were not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.
[]	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
[]	Enclosed is a copy of a non-English publication(s) English language publication (copy enclosed) claims priority from this non-English publication.
[]	Enclosed are abstracts of non-English publications, cited herein as documents respectively. English abstracts are attached to each document. An English abstract of non-English publication, document, may be found on the cover page of the publication.
[]	Enclosed is an English translation of non-English publications, cited herein as documents respectively. English translations are attached to each document.
[]	The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.:
	, filed, cited herewith as; and
	filed cited herewith as

#### **PATENT**



## Attorney Docket No. NUCL-006/01US Application No. 10/560,377 Page 3

This Information Disclosure Statement is filed within any one of the following time periods:

[ ]	within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
[]	within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
[x]	before the mailing date of a first office action on the merits; or
[]	before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Forms PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.

Dated: Feb. 27, 2007

USPTO Customer No. 58249 COOLEY GODWARD KRONISH LLP ATTN: Patent Group

The Bowen Building 875 15th Street, NW Suite 800 Washington, DC 20005-2221

Phone: (202) 842-7800 Fax: (202) 842-7899

Respectfully submitted,

COOLEY GODWARD KRONISH LLP

By:

Bonnie Weiss McLeod Reg. No. 43,255

Application No. Attorney Docket No. NUCL-006/01US 10/560,377 INFORMATION DISCLOSURE CITATION (Use several sheets if necessar 1 P E Applicants: Catherine J. PACHUK et al. PAGE 1 of 1 PTO Form 1449 FEB 9 7 2007 Int'l. Filing Date: June 10, 2004 Group Art Unit: To Be Assigned S. PATENT DOCUMENTS Name Class Sub-Class Filing Date Date Initial Document No. FOREIGN PATENT DOCUMENTS Class **Translation** Country Sub-Class Document No. Date OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Ford, "International Preliminary Report On Patentability," from PCT/US04/19229, filed June 10, 2004, 5 pages, 1. United States Patent and Trademark Office, IPEA/US, (mailed January 31, 2007). Giladi et al., "Small Interfering RNA Inhibits Hepatitis B Virus Replication in Mice," Mol. Ther. 8(5):769-776 2. (2003).Randall et al., "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," 3. Proc. Natl. Acad. Sci. USA 100(1):235-240 (2003). Date Considered Examiner Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.